Page 138 - 《中国药房》2020年23期

[18] GITT AK，DREXEL H，FEELY J，et al. Persistent lipid ab- Effect of the PCSK9 monoclonal antibody，AMG 145，in
normalities in statin-treated patients and predictors of homozygous familial hypercholesterolemia[J]. Circula-
LDL-cholesterol goal achievement in clinical practice in tion，2013，128（19）：2113-2120.
Europe and Canada[J]. Eur J Prev Cardiol，2012，19（2）： [28] RAAL FJ，HONARPOUR N，BLOM DJ，et al. Inhibition
221-230. of PCSK9 with evolocumab in homozygous familial hy-
[19] GIUGLIANO RP，DESAI NR，KOHLI P，et al. Efficacy， percholesterolaemia（TESLA part B）：a randomised，dou-
safety，and tolerability of a monoclonal antibody to pro- ble-blind，placebo-controlled trial[J]. Lancet，2015，385
protein convertase subtilisin/kexin type 9 in combination （9965）：341-350.
with a statin in patients with hypercholesterolaemia（LA- [29] RAAL FJ，HOVINGH GK，BLOM D，et al. Long-term
PLACE-TIMI 57）：a randomized，placebo-controlled， treatment with evolocumab added to conventional drug
dose-ranging，phase 2 study[J]. Lancet，2012，380（9858）： therapy，with or without apheresis，in patients with homo-
2007-2017. zygous familial hypercholesterolaemia：an interim subset
[20] HIRAYAMA A，HONARPOUR N，YOSHIDA M，et al. analysis of the open-label TAUSSIG study[J]. Lancet Dia-
Effects of evolocumab（AMG 145），a monoclonal anti- betes Endocrinol，2017，5（4）：280-290.
body to PCSK9，in hypercholesterolemic，statin-treated [30] LI C，LIN L，ZHANG W，et al. Efficiency and safety of
Japanese patients at high cardiovascular risk：primary re- proprotein convertase subtilisin/kexin 9 monoclonal anti-
sults from the phase 2 YUKAWA study[J]. Circ J，2014， body on hypercholesterolemia：a meta-analysis of 20 ran-
78（5）：1073-1082. domized controlled trials[J]. J Am Heart Assoc，2015. DOI：
[21] BLOM DJ，HALA T，BOLOGNESE M，et al. A 52-week 10.1161/JAHA.115.001937.
placebo-controlled trial of evolocumab in hyperlipi- [31] ZHANG XL，ZHU QQ，ZHU L，et al. Safety and efficacy
demia[J]. N Engl J Med，2014，370（19）：1809-1819. of anti-PCSK9 antibodies：a meta-analysis of 25 rando-
[22] SABATINE MS，GIUGLIANO RP，WIVIOTT SD，et al. mized，controlled trials[J]. BMC Med，2015. DOI：10.
Efficacy and safety of evolocumab in reducing lipids and 1186/s12916-015-0358-8.
cardiovascular events[J]. N Engl J Med，2015，372（16）： [32] GIUGLIANO RP，MACH F，ZAVITZ K，et al. Cognitive
1500-1509. function in a randomized trial of evolocumab[J]. N Engl J
[23] KOREN MJ，GIUGLIANO R，RAAL F，et al. Two year Med，2017，377（7）：633-643.
analysis of the safety and tolerability of evolocumab：the [33] GORDON T，KANNEL WB，CASTELLI WP，et al. Lipo-
OSLER-1 study[J]. J Am Coll Cardiol，2015. DOI：10. proteins，cardiovascular disease，and death：the Framing-
1016/S0735-1097（15）61364-X. ham study[J]. Arch Intern Med，1981，141（9）：1128-1131.
[24] KOREN MJ，SABATINE MS，GIUGLIANO RP，et al. [34] RUDOLPH AE，SILLESEN H，SIMUNOVIC L，et al.
Long-term low-density lipoprotein cholesterol-lowering Stroke prevention by aggressive reduction in cholesterol
efficacy，persistence，and safety of evolocumab in treat- levels（SPARCL）investigators：high-dose atorvastatin af-
ment of hypercholesterolemia results up to 4 years from ter stroke or transient ischemic attack[J]. N Engl J Med，
the open-label OSLER-1 extension study[J]. JAMA Car- 2006，355（54）：549-559.
diol，2017，2（6）：598-607. [35] HEIKKILA P，KAHRI AI，KOVANEN PT，et al. Effects
[25] SULLIVAN D，OLSSON AG，SCOTT R，et al. Effect of a of mevinolin，an inhibitor of cholesterol synthesis，on the
monoclonal antibody to PCSK9 on low-density lipopro- morphology and function of differentiating and differen-
tein cholesterol levels in statin-intolerant patients：the tiated rat adrenocortical cells in primary culture[J]. Cell
GAUSS randomized trial[J]. JAMA，2012，308（23）： Tissue Res，1990，261（1）：125-132.
2497-2506. [36] BLOM DJ，DJEDJOS CS，MONSALVO ML，et al. Ef-
[26] RAAL FJ，STEIN EA，DUFOUR R，et al. PCSK9 inhibi- fects of evolocumab on vitamin E and steroid hormone
tion with evolocumab（AMG 145）in heterozygous fami- levels results from the 52-week，phase 3，double-blind，
lial hypercholesterolaemia （RUTHERFORD-2）：a ran- randomized，placebo-controlled DESCARTES study[J].
domised，double-blind，placebo-controlled trial[J]. Lancet， Circ Res，2015，117（8）：731-741.
2015，385（9965）：331-340. （收稿日期：2020-07-01 修回日期：2020-11-05）
[27] STEIN EA，HONARPOUR N，WASSERMAN SM，et al. （编辑：罗 瑞）

·2944 · China Pharmacy 2020 Vol. 31 No. 23 中国药房 2020年第31卷第23期